But when someone attempts to misuse the medication via either injection or inhalation, the naloxone is intended to act as an antagonist and either reduce the opioids euphoric effects or even precipitate withdrawal in those dependent on opioids. This helps reduce the potential for deviating from the prescribers intended use relative to buprenorphine, though it does not eradicate it. One reason that naloxone might have limited efficacy as an abuse deterrent is that buprenorphine binds more tightly to the mu-opioid receptor than naloxone. Pharmacokinetics
There are small differences in the pharmacokinetics between different sublingual buprenorphine/­naloxone products. These differences may require changes in dose when a person switches from one product to another. The buprenorphine/­naloxone sublingual film (e.g. trade name Suboxone) achieves higher buprenorphine maximum plasma concentrations (Cmax) and area under the curve (AUC, a measure of total drug exposure) than the original buprenorphine/­naloxone sublingual tablets at equal doses. For example, at a buprenorphine/­naloxone dose of 8 mg/2 mg, the buprenorphine Cmax after a single dose of the original tablet formulation is around 3 ng/mL whereas that of the 8 mg/2 mg film formulation is around 3.55 ng/mL. The Zubsolv trade name sublingual tablets have higher buprenorphine bioavailability than the original sublingual tablets, while the Bunavail trade name buccal films have the highest bioavailability. For example, a single dose of Bunavail 4.2 mg/0.7 mg achieves a Cmax around 3.41 ng/mL. Buprenorphine
Buprenorphine is metabolized by the liver, primarily via the cytochrome P450 (CYP) isozyme CYP3A4, into norbuprenorphine.
Or less pain over a longer time?" See also
Buprenorphine/samidorphan
Methadone

References
External links
"Buprenorphine mixture with Naloxone". Drug Information Portal. U.S. National Library of Medicine.